Proinflammatory Immature Myeloid Cells and Their Use in Treatment of Cancer
Generated by an autonomous AI research agent — Anthropic Claude Opus 4.7 or OpenAI GPT-5.5, max reasoning effort. Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.
Indication
Cancer (broad, all tissue types)
Modality
Gene Therapy
Mechanism
Gene-edited myeloid cell immunotherapy
Target
—
rNPV Envelope
Low
-$54.5M
costs +25% · peak −25%
Base
-$38.1M
cumulative PoS 2.3%
High
-$21.7M
costs −25% · peak +25%
Costs and durations follow ex-vivo autologous cell-therapy norms anchored to the Iovance lifileucel and Carisma CAR-M development arcs (cell-therapy preclinical/IND-enabling premium; long Phase 1 to establish CRISPR-edited human myeloid manufacturing). PoS is held well below cell-therapy averages and stacked conservatively: preclinical-to-phase-2 PoS reflects that published p50-IMC efficacy required co-administered 5-FU (monotherapy did not slow tumors) and was MHC-match-dependent in mice, so translational and proof-of-concept risk is high. Cumulative LoA ≈ 2.4%, consistent with the cohort's 6–11% ceiling for de-risked top-10 assets and appropriately lower here.
Composite score breakdown
Locked rubric — 40/30/30 weights
Clinical relevance · 40%
0.70
Modality fit · 30%
0.74
Whitespace · 30%
0.50
Composite 0.652 — composite-score rank #19 of 50 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#30) to match the index ordering.
Comparators
Real programs anchoring the engine inputs
CT-0508 / CT-0525 (Carisma Therapeutics) — ex-vivo engineered HER2 CAR-macrophage / CAR-monocyte
Closest mechanism-and-modality precedent: ex-vivo manufactured, genetically engineered autologous myeloid (macrophage/monocyte) cell therapy for solid tumors. CT-0508 Phase 1 (NCT04660929) established human feasibility, manufacturability, and a tolerable safety profile but showed only stable disease / no meaningful monotherapy responses. CAUTIONARY STATUS: Carisma wound down ex-vivo CAR-M recruitment, paused all R&D, lost Moderna research funding, and reduced workforce ~95% by 2025 — it is the sector's bellwether and its trajectory is the single most important precedent for an academic engineered-myeloid-cell program.
Criteria 1 and 2: same mechanism class (genetically engineered pro-inflammatory myeloid cell adoptive therapy) and same indication space (solid tumors) with the only clinical-stage ex-vivo engineered-myeloid program; retained as a status-flagged cautionary precedent, not a live anchor.
MT-302 (Myeloid Therapeutics) — in vivo mRNA/LNP TROP2 CAR myeloid reprogramming
Active mechanism-class comparator: reprograms circulating myeloid cells to a pro-inflammatory, CAR-bearing phenotype. First-in-human data at ASCO 2025 showed selective myeloid CAR expression, increased pro-inflammatory gene signatures across tumor types, a favorable safety profile, and ongoing Phase 1 dose escalation. Mechanistically parallel to the JHU p50-IMC pro-inflammatory-myeloid thesis but delivered in vivo via mRNA/LNP rather than ex-vivo CRISPR knockout — frames both the competitive landscape and the regulatory/endpoint path for pro-inflammatory myeloid immunotherapy.
Criteria 1: same mechanism class (induced pro-inflammatory myeloid anti-tumor phenotype) with an active clinical-stage program; closest currently-advancing analog and a competitive-threat anchor.
Amtagvi (Iovance Biotherapeutics) — lifileucel autologous TIL cell therapy
Regulatory and commercial archetype anchor (NOT a mechanism match): the first autologous adoptive cell therapy approved for a solid tumor (FDA accelerated approval, Feb 2024) at a $515,000 per-treatment list price. Used only to calibrate ex-vivo autologous-cell-therapy development cost, manufacturing duration, accelerated-approval pathway feasibility, and gene/cell premium pricing — it does not validate the p50-IMC mechanism.
Criteria 3 and 4: same regulatory pathway (accelerated approval for an autologous solid-tumor cell therapy) and same broad modality (ex-vivo autologous cell therapy) for cost/duration/pricing calibration only; explicitly an archetype anchor, not a mechanism comparator.
Stage profile
Asset-specific cost, duration, and PoS by stage
| Stage | Cost | Duration | PoS | Citations |
|---|---|---|---|---|
| Preclinical | $22.0M | 30 mo | 42.0% | [0] [1] [2] |
| Phase I | $60.0M | 24 mo | 55.0% | [3] [4] |
| Phase II | $130.0M | 30 mo | 26.0% | [3] [4] [5] |
| Phase III | $240.0M | 36 mo | 48.0% | [5] [6] |
| NDA/BLA Review | $16.0M | 12 mo | 80.0% | [5] [6] |
Multiplier handling: No multipliers eligible for this asset under the locked methodology. See methodology for the rule.
Peak revenue and discount rate
$700.0M peak · WACC 15.0%
Peak revenue. Modeled on the Iovance lifileucel archetype: an ex-vivo autologous solid-tumor cell therapy commands gene/cell premium pricing (~$0.5M+ per treatment) but is constrained by apheresis-to-manufacture logistics, lymphodepletion burden, and a heavily pre-treated salvage population. $700M reflects a realistic risk-shared peak for a single autologous engineered-myeloid product launching into a defined refractory solid-tumor segment (not 'all tissue types'), well below CAR-T franchise peaks because manufacturing complexity and the unproven monotherapy mechanism cap penetration. This figure is illustrative for cohort rNPV consistency; the realistic value path is a strategic partnership, so peak product revenue would in practice be shared via milestones/royalties, not captured standalone by JHU.
WACC. A preclinical, mechanism-unproven, ex-vivo autologous cell-therapy concept in a sector whose lead company (Carisma) collapsed sits at the high end of biotech discount rates (15%), above mainstream cell therapy (13–14%) to reflect platform, manufacturing, and sector-viability risk.
Sensitivity (tornado)
Top drivers of rNPV variance
Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV (-$38.1M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.
Monte Carlo distribution
1,000 trials · rpNPV mode
This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).
P5
-$158.7M
P25
-$67.9M
P50 (median)
-$24.5M
P75
-$14.0M
P95
-$7.4M
Prob ≥ 0
2.0%
Comparable launch curves
Revenue trajectories of named comparators
Amtagvi (Iovance Biotherapeutics) — lifileucel autologous TIL cell therapy
Launched 2024 · peak $570.0M (estimated)
Evidence register
8 per-assumption citations
| Assumption | Source | Date | Confidence |
|---|---|---|---|
p50-IMC required 5-FU co-administration; monotherapy did not slow tumors (preclinical PoS basis) stage_profile.preclinical.pos | NF-κB p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma peer_review | 2020-01-01 | high |
Efficacy was MHC-match-dependent in mice (translational/patient-specificity risk) stage_profile.phase_2.pos | Adoptive transfer of immature myeloid cells lacking NF-κB p50 (p50-IMC) impedes the growth of MHC-matched high-risk neuroblastoma peer_review | 2021-01-01 | high |
Asset is preclinical: proof-of-concept in mouse and human cells only; PCT pending; no IND stage_profile.preclinical.duration_months | Proinflammatory Immature Myeloid Cells and Their Use in Treatment of Cancer (JHTV C18356) regulatory | 2025-09-23 | high |
Ex-vivo engineered-myeloid cell therapy human feasibility and safety precedent stage_profile.phase_1.pos | Carisma Announces Latest Data from Phase 1 Clinical Trial of CT-0508 at 8th Annual CAR-TCR Summit news | 2023-09-18 | high |
Engineered-myeloid sector viability cautionary precedent (Carisma wind-down) wacc_suggestion | Carisma Therapeutics Provides Corporate Updates news | 2025-03-31 | high |
Active mechanism-class competitor: in vivo pro-inflammatory myeloid reprogramming (MT-302) comparators[1] | Myeloid Therapeutics Unveils First-in-Human In Vivo mRNA CAR Data at the 2025 ASCO Annual Meeting news | 2025-05-30 | high |
Autologous solid-tumor cell-therapy regulatory pathway and premium pricing archetype peak_revenue_usd | Lifileucel: First Cellular Therapy Approved for Cancer (NCI Cancer Currents) regulatory | 2024-02-16 | high |
Peer-reviewed CAR-macrophage first-in-human translational context comparators[0] | Chimeric Antigen Receptor-Macrophage Therapy Enters the Clinic: The First-in-Human Trial for HER2+ Solid Tumors peer_review | 2024-09-01 | medium |
Thesis
Why this asset earns its rank
This Johns Hopkins asset is a genuine but very early therapeutic concept: ex-vivo immature myeloid cells in which CRISPR/Cas9 knocks out NF-κB p50 (NFKB1) to lock them into a pro-inflammatory, T-cell-activating phenotype that resists tumor-microenvironment suppression, then re-infuses them as an adoptive cell therapy. The underlying p50-IMC biology is real and peer-reviewed across murine prostate, pancreatic, glioblastoma, and high-risk neuroblastoma models from the same group. Two facts a CMO will surface in minute one are disclosed up front: in the published preclinical work p50-IMC alone did not slow tumor growth — efficacy required co-administered 5-fluorouracil — and anti-tumor activity was MHC-match-dependent (it failed in MHC-mismatched tumors). The value-proposition phrase 'high potential as anti-cancer therapy' therefore overstates a monotherapy that has not been demonstrated, and the rubric's 'broad, all tissue types' indication is indefensibly wide for a preclinical asset with a PCT only filed in December 2025 and no IND. A pinned-bucket caveat also applies: the published modality is gene_therapy, but mechanistically this is an ex-vivo CRISPR-edited autologous myeloid CELL therapy — the bucket is left pinned per methodology and mechanism-true cell-therapy comparators are used.
The comparator set is anchored to the only clinical-stage analogs. Carisma's CT-0508/CT-0525 ex-vivo engineered-myeloid program proved human manufacturability and safety but no monotherapy efficacy, and — critically — Carisma paused all R&D, lost Moderna funding, and cut ~95% of staff by 2025, making the engineered-myeloid sector's bellwether a cautionary, not encouraging, precedent. Myeloid Therapeutics' MT-302 is the active mechanism-class competitor (in vivo mRNA pro-inflammatory myeloid reprogramming, Phase 1 ongoing). Iovance's lifileucel is used only as the autologous solid-tumor cell-therapy regulatory/pricing archetype ($515K/treatment, accelerated approval). The engine result is -$54.5M to -$21.7M, with a base rNPV of -$38.1M and cumulative PoS of 2.3%; that wide, conservative spread reflects an unproven monotherapy mechanism, a punishing ex-vivo autologous cost structure, and a sector whose lead company collapsed — which is why the economics point to a partner, not standalone equity.
Verdict: a mechanistically interesting, well-published academic immuno-oncology concept that earns its rank chiefly on clinical-relevance (immune-exclusion is a real checkpoint-resistance bottleneck), a high gene/cell modality_pos score, and high IRA exposure — not on de-risked productizability. It is a partnership_candidate: the honest path is a strategic/pharma collaborator who can absorb cell-therapy manufacturing and run the 5-FU-combination, biomarker-defined, MHC-matched (autologous) translational work, with JHU capturing milestones and royalties rather than standalone product economics.
Key risks
Asset-specific, not generic biotech risks
- Monotherapy efficacy is unproven: in the published p50-IMC studies, cells alone did not slow tumor growth — the ~3-fold effect required co-administered 5-fluorouracil — so the clinical product is realistically a chemo-combination regimen, not the standalone 'anti-cancer therapy' the value proposition implies.
- Translational gap: efficacy was MHC-match-dependent and was generated with germline p50-knockout mouse cells; whether CRISPR-edited human immature myeloid cells reproduce the pro-inflammatory, fibrosis/tumor-controlling phenotype — and persist in patients — is entirely unvalidated clinically.
- Sector-viability risk: Carisma, the only company to take ex-vivo engineered myeloid cells into the clinic, showed no monotherapy responses and then wound down R&D, lost its Moderna partnership, and cut ~95% of staff — a direct cautionary precedent for an academic engineered-myeloid program seeking a partner or capital.
- Indication overreach: a preclinical asset cannot defensibly claim 'broad, all tissue types' oncology; the asset needs a single biomarker- or tumor-type-defined lead indication with a credible patient-selection strategy before any rNPV is meaningful.
- Modality-bucket vs reality: classified gene_therapy but operationally an ex-vivo CRISPR-edited autologous myeloid cell therapy, inheriting apheresis-to-manufacture logistics, lymphodepletion burden, and per-patient COGS that compress commercial value and reinforce the partnership path.